Lisdexamfetamine, sold under the brand name Vyvanse among others, is a medication that is a derivative of amphetamine. It is mainly used to treat attention deficit hyperactivity disorder (ADHD) in people over the age of five as well as moderate-to-severe binge eating disorder in adults. Lisdexamfetamine is taken by mouth. In the United Kingdom, it is usually less preferred than methylphenidate. Its effects generally begin within 2 hours and last for up to 14 hours. Common side effects of lisdexamfetamine include loss of appetite, anxiety, diarrhea, trouble sleeping, irritability, and nausea. Rare but serious side effects include mania, sudden cardiac death in those with underlying heart problems, and psychosis. It has a high potential for substance abuse per the DEA. Serotonin syndrome may occur if used with certain other medications. Its use during pregnancy may result in harm to the baby and use during breastfeeding is not recommended by the manufacturer. Lisdexamfetamine is a central nervous system (CNS) stimulant that works after being converted by the body into dextroamphetamine. Chemically, lisdexamfetamine is composed of the amino acid L-lysine, attached to dextroamphetamine. Lisdexamfetamine was approved for medical use in the United States in 2007. In 2018, it was the 82nd most commonly prescribed medication in the United States, with more than 10 million prescriptions. It is a Schedule II controlled substance in the United Kingdom and a Schedule II controlled substance in the United States.[from Wikipedia]
|